Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.

By E. Maser, Renata M. Villela, M. Silverberg, G. Greenberg. Clinical Gastroenterology and Hepatology, 2006

647 citations recorded by the source corpus.

Subfields: Genetics, Immunology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/5623cbd5519e470d25aa1e0bf43fedd32daacab3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Colombel

In Rheumatology

1. J. Colombel

Citations in the corpus

• Guidelines for the management of inflammatory bowel disease in adults (2011, background): “There is emerging evidence linking low serum trough levels of IFX to lack of sustained response.”
• Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. (2012, background): “Previous surgical resection, n (%) 25 (22) CDAI 37 (19–61) reatment history Antimetabolite treatment Methotrexate, n (%) 19 (17) Azathioprine/6-mercaptopurine, n (%) 96 (83) Antimetabolite naïvea at infliximab initiation, n (%) 51 (44)”